http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102584981-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_57fa60a0cac09d94577be5413e9c1e30 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-16 |
| filingDate | 2012-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28f76bbc531ba04e129df13f63b1e10e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a55805bc5663e452dd7b21fb390eee00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c8d803efebcfed8f73e034df226da7 |
| publicationDate | 2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102584981-B |
| titleOfInvention | Mutant of interferon alpha and polyethylene glycol derivatives of mutant |
| abstract | The invention belongs to the field of biomedicines and relates to a cysteine mutant of a composite interferon, polyethylene glycol derivatives of the mutant, a preparation method of the polyethylene glycol derivatives, a medicament composition, and application of the composite interferon and the polyethylene glycol derivatives in preparation of medicaments treating viral diseases. The cysteine mutant of the composite interferon is formed in the way that amino acid at one selected from the 160th site to the 162th site, counting from an N end in the amino acid sequence of the composite interferon, mutates into the cysteine; and the polyethylene glycol derivatives of the mutant of the cysteine are obtained by connection of the cysteine mutant of the composite interferon and a polyethylene glycol modifier, wherein the molecular weight of the polyethylene glycol modifier ranges from 5KDa to 40KDa. The cysteine mutant of the composite interferon and the polyethylene glycol derivatives of the mutant disclosed by the invention have higher biological activities, better pharmacologic action and stability, and more reliable safety. |
| priorityDate | 2012-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 169.